ACQUISITIONS (Details) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | |
|---|---|---|---|---|
|
Apr. 30, 2024
USD ($)
|
Oct. 31, 2023
USD ($)
Right
$ / shares
|
Sep. 30, 2024
USD ($)
|
Sep. 30, 2024
USD ($)
|
|
| ACQUISITIONS | ||||
| Transaction costs | $ 2,645 | |||
| Acquired in-process research and development expense | $ 42,595 | |||
| Zynerba Acquisition | ||||
| ACQUISITIONS | ||||
| Cash consideration per common stock | $ / shares | $ 1.1059 | |||
| Aggregate consideration | $ 60,000 | |||
| Number of contingent value right per common stock | Right | 1 | |||
| Contingent consideration per common stock | $ / shares | $ 2.5444 | |||
| Epygenix Acquisition | ||||
| ACQUISITIONS | ||||
| Aggregate consideration | $ 32,686 | |||
| Transaction costs | 450 | |||
| Asset acquisition, upfront consideration paid | 35,000 | |||
| Amount of fee payable upon achieving development and regulatory milestones | 130,000 | |||
| Amount of fees payable upon achieving sale-based milestones | $ 515,000 | |||
| Acquired in-process research and development expense | $ 17,095 | $ 17,095 |